Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application

Lingjia Xu and Jiali Pu

Department of Neurology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China

Correspondence should be addressed to Jiali Pu; carrie1105@163.com

Received 15 April 2016; Revised 3 July 2016; Accepted 10 July 2016

1. Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1] and is defined as one of the synucleinopathies, which include other disorders featuring Lewy bodies [2]. It is characterized by the relatively selective loss of dopaminergic neuronal cells in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies and Lewy neurites in surviving affected neurons [3]. As the main component of the Lewy bodies and Lewy neurites, \( \alpha \)-synuclein is the product of the first gene identified as associated with PD: SNAC, which was reported in 1997 by Polymeropoulos et al. [4]. Mutations in SNCA (duplications, triplications, or point mutation) cause autosomal dominant forms of PD and are the basis of the risk of developing sporadic PD [5]. Recent studies [6–8] suggested that the misfolding of \( \alpha \)-synuclein causes it to aggregate and spread in certain sites, where the inflammation induced by it is intimately involved in the pathogenetic dysfunction underlying PD. All this indicates that \( \alpha \)-synuclein plays a central role in the pathogenesis of PD.

Currently, the main treatment for PD is replacement therapy using levodopa, which may be effective in the early stage of the disease [9]. However, as the disease progresses, levodopa has less effect, and a series of side effects, such as movement complications, occur. Therefore, other therapeutic strategies, such as deep brain stimulation (DBS), have also been attempted for advanced patients; however, it is only an alleviative treatment. Consequently, biomarkers for early diagnosis and neuroprotective therapy are urgently required for this chronic disorder. Alpha-synuclein is the distinctive hallmark of PD; therefore, it has a potential application in the clinical diagnosis and treatment of PD [10].

To fully understand the pathogenetic dysfunction of \( \alpha \)-synuclein associated with PD, in this review, we summarize the current knowledge of the physiology and pathology of \( \alpha \)-synuclein, including its structure, physiological function, degradation, spread, and toxicity. We also highlight current approaches that seek to develop this protein as a potential diagnostic biomarker and therapeutic target.

2. Alpha-Synuclein Structure and Physiological Function

In humans, \( \alpha \)-synuclein is a member of a three-protein family: \( \alpha \)-synuclein, \( \beta \)-synuclein, and \( \gamma \)-synuclein [11]. Alpha-synuclein is a small protein comprising 140 amino acids...
with three domains: an N-terminal domain (aa 1–65), a non-amyloid-β component of plaques (NAC) domain (aa 66–95), and a C-terminal domain (aa 96–140) [12]. Rare point mutations in the N-terminal domain of α-synuclein, such as Ala53Thr, Ala30Pro, Glu46Lys, and the recently described His50Gln, Gly51Asp, and Ala53Glu, result in autosomal dominant familial PD and PD-like syndromes, presumably caused by misfolding and/or aggregation of the mutant α-synuclein protein [4, 13–17]. All known clinical mutations are present in this N-terminal region [10], emphasizing the importance of this domain in the pathological dysfunction of α-synuclein. The NAC domain, which is unique to α-synuclein [18], has a stretch of 12 amino acid residues that are responsible for the aggregation properties of α-synuclein via inhibition of its degradation and promotion of its fibrillation [19]. Nowadays, most studies focus on the N-terminal peptide; however, future studies should also consider the C-terminal peptide, because this is where truncation more typically occurs [20]. The truncations discovered to date include Tyr39T, Tyr125T, Tyr133T, and Tyr136T [10]. To date, very few studies have investigated the effects of the smallest peptide produced by truncation. Research on this peptide might give us a new and distinct view of the potential application of this protein.

Concerning the native state of α-synuclein, there are two hypotheses: one is the monomeric conformation, and the other one is the α-helically folded tetramer. Early studies of α-synuclein isolated from bacterial expression systems or mouse tissues indicated that it is monomeric, with a limited secondary structure [21]; however, Bartels et al. [22] identified the state of endogenous α-synuclein in living human cells by examining freshly collected human red blood cells and showed that natively, endogenous cellular α-synuclein exists largely as an α-helically folded, 58 kDa tetramer. They hypothesized that the contrasting results might have resulted from the different materials and protocols applied in this research, namely, denaturing detergents. The tetramer circulating in plasma and can become destabilized which promotes α-synuclein aggregation from monomers to oligomers. Further studies by Burre et al. [23], using similar methods in the mouse brain, indicated that the predominant native conformation of α-synuclein might be an unstructured monomer, exhibiting a random coil structure in solution, and it can aggregate age-dependently, while the α-helical structure was only adopted upon membrane binding [24].

However, the normal physiological structure and function of α-synuclein still remain unclear. Recent studies showed that the normal physiological function of α-synuclein involves roles in compartmentalization, storage, and recycling of neurotransmitters [25]. In addition, α-synuclein is associated with the physiological regulation of certain enzymes and is thought to increase the number of dopamine transporter molecules [26]. Neurotransmitter release [27] and interaction with the synaptic SNARE- (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) complex are partly mediated by its role as molecular chaperone [23]. Cycling between SNARE-complex assembly and disassembly is required, with continuous generation of reactive SNARE-protein intermediates. Cysteine string protein α (CSPα) is a chaperone that is essential for synaptic health, whose deletion in mice led to a decrease in the SNARE-complex, nerve terminal degeneration, motor impairment, and cell death [28]. In CSPα knockout mice, α-synuclein could rescue this degenerative phenotype and restore levels of SNARE-complexes in synaptic terminals. Moreover, mice lacking both α-synuclein and CSPα exhibited nerve terminal dysfunction and cell death [29]. These findings suggested that α-synuclein is able to complement the activity of CSPα as a molecular chaperone. This interaction was documented in further research in which α-synuclein was demonstrated to directly bind to the SNARE-protein synaptobrevin-2 and promote SNARE-complex via binding of its C-terminal 44 residues to the N-terminal 28 residues from synaptobrevin-2 [30].

3. Alpha-Synuclein Aggregation, Degradation, and Spread

Alpha-synuclein exists in various conformations in a dynamic equilibrium, modulated by many factors, comprising internal and external factors that either accelerate or inhibit fibrillation [31–33]. As mentioned before, disease-related mutations affect the aggregation of α-synuclein (Figure 1). All known mutations associated with familial PD (Ala53Thr, Ala30Pro, Glu46Lys, His50Gln, Gly51Asp, and Ala53Glu) are found in the N-terminal domain [10]. The mutations Glu46Lys, His50Gln, and Ala53Glu [14, 15, 17] can promote α-synuclein to form insoluble aggregates and produce oligomers. However, how these mutations accelerate aggregation has not been completely clarified. Based on Burre et al.’s later study [30], it is likely to be due to the destabilization of the native N-terminal conformation. The NAC domain plays a central role in α-synuclein’s self-propagation [19]. Recently, Rodriguez et al. [34] resolved the crystal structures of residues 68–78 (termed NACore) and residues 47–56 (PreNAC) using microelectron diffraction, which revealed that, in certain regions, these strands transferring into β-sheets are typical of amyloid assemblies. Lastly, the C-terminal domain was identified to be necessary to maintain the solubility of α-synuclein. The presence of residues consisting of five prolines suggested that this region lacks secondary structure [35]. In addition, C-terminally truncated forms of α-synuclein appeared to aggregate faster than the full-length protein [36, 37]. In addition, the C-terminus appears to be important for the interaction of α-synuclein with other proteins in the nervous system and with some small molecules [23]. These findings indicated that all three domains play a role in aggregation and that they might influence each other, either promoting or inhibiting its pathological fibrillation and oligomerization.

Phosphorylation of α-synuclein is essential and sufficient in the process of degradation in neurodegenerative diseases. Mass methodologies revealed that α-synuclein extracted from human Lewy bodies was phosphorylated at Ser129 [38]. Some data indicated that polo-like kinase (PLK) 2-mediated phosphorylation of Ser129 increased autophagy-mediated degradation of α-synuclein, suggesting that phosphorylation might be a neuroprotective mechanism to accelerate the clearance of aggregated protein [39]. Chemical
nitration of α-synuclein resulted in the formation of both tyrosine-nitrated monomers and nitrated dimers [40], which also affected the degradation of α-synuclein, and immunoelectron microscopy confirmed that nitrated monomers and dimers are incorporated into amyloid fibrils. Purified nitrated α-synuclein monomer by itself was unable to form fibrils, whereas the nitrated dimer accelerated the aggregation of unmodified α-synuclein [41]. Additionally, nitration of certain residues in the N-terminal domain decreased binding to synthetic vesicles and prevented the protein from adopting the α-helical conformation to the membrane [41]. The structure has been identified by Snead and Eliezer [42], clarifying the physiological function of α-synuclein binding to the membrane. Using the synthetic nitrated α-synuclein, the results showed that nitration did not interfere with phosphorylation of S129 by PLK3 and reaffirmed that intermolecular interactions between the N- and C-terminal domains of α-synuclein are critical to direct nitration-induced oligomerization of α-synuclein [30].

Alpha-synuclein is degraded by the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway [43]. Ebrahimi-Fakhari et al. [44] provided in vivo evidence that normal soluble α-synuclein is degraded mainly by the UPS, whereas more complex conformations, including aggregates, are degraded by the autophagy-lysosomal pathway. The finding that α-synuclein in both the monomeric and oligomeric states can be detected in human plasma, cerebrospinal fluid, and other peripheral tissues [45, 46] suggested the idea that α-synuclein is secreted. Although the exact mechanism of α-synuclein’s release has not been fully demonstrated, it seems that α-synuclein might be released by exosomes in a calcium-dependent manner and be further degraded after lysosomal inhibition [47]. Lööv et al. [48] found that insoluble conformations of α-synuclein do not themselves appear to have significant neurotoxic effects, despite being misfolded and even aggregated in certain areas. By contrast, various α-synuclein oligomers are harmful, and structures termed extracellular vesicles (EVs) might mediate the propagation of toxic α-synuclein between neurons [48]. In one study, recombinant α-synuclein monomers produced together with EV fractions from cultured neuroblastoma cells accelerated the formation of toxic oligomers compared with monomeric α-synuclein produced alone [49]. EVs are mediators of cellular information; thus, genetic information
can be carried from one cell to another and consequently can aggravate the toxicity [50]. In conclusion, propagation and spreading are key to the pathogenetic dysfunction in PD. Recent in vivo and in vitro studies [26] confirmed that transfer and interaction through the membranes by α-synuclein might contribute to the pathogenetic dysfunction in PD and thus progress the disease. These results suggest that α-synuclein propagation is a major factor in the progression of PD pathology.

Moreover, numerous data have suggested that α-synuclein self-propagates [7]. Normally, small numbers of aggregates are disposed of by the protein degradation pathways; however, if, over time, the aggregates accumulate above a certain threshold, they could self-propagate, contributing to the progression of PD. Lewy bodies and neurites, a histopathological signature of PD, found in grafted fetal dopaminergic neurons in the SNpc of PD patients, are of significant importance [51]. These observations led to the development of the “prion-like hypothesis” [51]. Several in vitro and in vivo studies suggested that α-synuclein can spread from cell to cell and from region to region, which dramatically promotes PD pathogenesis and progression [52–58]. Recently, one of these studies focused on the postmortem analyses of brains from patients with PD who received fetal mesencephalic transplants and demonstrated that α-synuclein-containing Lewy bodies gradually appeared in the grafted neurons [53]. Subsequently, The authors in [53] seeded α-synuclein aggregates in recipient neurons to explore whether intercellular transfer of α-synuclein could occur from the host to the graft. Ultimately, they demonstrated that α-synuclein could transfer between host cells and grafted dopaminergic neurons. In summary, intercellularly transferred α-synuclein can propagate its pathology by interacting with cytoplasmic α-synuclein. However, whether the pathological conversion of endogenous α-synuclein is triggered by material derived from patients with PD or from recombinant α-synuclein remains to be discussed. In addition, whether preformed fibrils might occur directly through a seeding prion process or occur indirectly as a general response to cellular stress remains unknown.

4. Alpha-Synuclein Toxicity in PD

The precise mechanism whereby α-synuclein leads to toxicity and cell death remains obscure. It is likely that aggregation of α-synuclein results either from an increased release of α-synuclein and increased cell–to-cell transfer or via accumulated cellular levels of the protein [38]. Here, we discuss the latest research in this area.

Alpha-synuclein’s toxicity is interconnected with its physiological function, and to better understand its toxicity, animal models, including wild-type ones and those with genetic mutations, are needed. One of the most important physiological functions that α-synuclein regulates, synaptic activity, was tested directly in mice lacking α-synuclein. Originally, α-synuclein null mice develop normal brain architecture and contacts and do not exhibit gross behavioral phenotypes [59]. Upon repeated stimulation, dopaminergic synapses from α-synuclein null mice showed highly elevated dopamine release [59]. In α/β-synuclein double knockout mice, synaptic plasticity appears unaltered relative to α-synuclein single knockouts, although the dopamine levels in the striatum were reduced [60]. Meanwhile, in the α/β/γ-synuclein triple knockout mice, the synucleins were proved to be very important, because of the decreased life span and age-dependently synaptic dysfunction compared with wild-type mice [23]. Collectively, these reports emphasized the important role of the synucleins in long-term synaptic maintenance and flexibility. Kokhan et al. [61] carried out behavioral evaluations in α-synuclein knockout mice, and the results showed that α-synuclein knockout mice had worse learning ability in tests requiring both working and spatial memory. For the first time, they demonstrated that α-synuclein is necessary for these types of learning and explained this phenomenon by discussing neurotransmitters involved in the pathology of cognitive dysfunction, like monoamine, glutamate, and acetylcholine-mediated neurotransmission [61]. The physiological function and pathological dysfunction of α-synuclein are both involved in synaptic neuronal transmitters, which prompts the question as to what triggers this protein’s toxicity.

The neuronal toxicities of α-synuclein caused by genetic mutations or epigenetic mechanisms appear to involve many pathways and cellular functions, including endocytosis, Golgi homeostasis, ER-to-Golgi transport, presynaptic trafficking, UPS, autophagy, ER, and oxidative and nitration stress [62–64]. Alpha-synuclein oligomers are thought to be the toxic species and the cause of the neurodegenerative process. These oligomers would spread throughout the brain and other parts of body and induce α-synuclein pathology in interconnected structures [48].

There are several pathological factors that contribute to the toxicity of α-synuclein. Firstly, dysfunction of autophagy and UPS, the two main ways to clear toxic α-synuclein [65, 66], might lead to neuronal toxicities; secondly, both nitration and oxidation decrease the propensity of α-synuclein to form stable conformations, which might contribute to the progression of PD; in addition, truncated α-synuclein species have also been reported in Lewy bodies [20]. Truncation, typically occurring in the C-terminal domain of the protein, is associated with an increased propensity of α-synuclein to form fibrils and with increased toxicity in fly and rat models of PD [67, 68]. Currently, inflammation is a hot topic in studies of the pathogenesis in PD. Glial cells are the culprit in the mechanism of neuroinflammation, and this makes sense considering the prion-like hypothesis of α-synuclein’s spread throughout the brain. The direct transfer of α-synuclein from neurons to astrocytes was demonstrated in vivo using transgenic mice overexpressing human α-synuclein under a neuronal promoter by Lee et al. [69]. In these transgenic mice, accumulation of human α-synuclein was observed not only in neurons, but also in glial cells [69]; the authors also found that the secretion of α-synuclein by neurons induced toxicity not only inside the cytoplasm of neighboring cells, but also in the extracellular space. The results clarified what activates glial cells and induces chronic inflammation, thereby contributing to the progression of the pathology throughout the brain. In other reports, the preferential binding of iron, copper, and other metals, including Cu(II), Mn(II), Co(II), and Ni(II),
to the C-terminus of α-synuclein at residues DI21, N122, and E123 [70, 71] has been shown to influence α-synuclein’s function and aggregation and to promote the disease.

The spread of α-synuclein suggests that its toxicity would affect both the nervous system and other systems throughout the human body. This prompted us to consider the relationship between α-synuclein and the nonmotor symptoms in PD, such as the deficit of the olfactory sensation and astirction, which are nonspecific and always appear before the motor symptoms. Olfactory filaments are the only nerves directly exposed to the exterior environment [10, 56]. Transgenic animals expressing human α-synuclein under the control of the tyrosine hydroxylase promoter (ensuring catecholaminergic neuron-specific expression) presented olfactory impairments compared with wild-type animals during the olfaction test, and the olfactory deficits appeared long before the motor alterations in that study [52]. This brain region is of particular interest, because Lewy neurites and bodies are present in this area in the very early stages of PD [52]. This also provided a new insight into the toxicity of α-synuclein and its potential as a biomarker. However, it remains to be determined whether the misfolding of α-synuclein occurs randomly, where and when it first appears, and how self-propagation is initiated.

5. Alpha-Synuclein as a Diagnostic Biomarker in PD

To date, the diagnosis of PD still relies mostly on clinical features, because neuropathological confirmation is only possible with autopsy examination in postmortem studies [72]. Early diagnosis is required urgently, since PET-CT (Positron Emission Computed Tomography) or functional MRI (Magnetic Resonance Imaging) scans are not specific enough for this disease. Alpha-synuclein, with its unique characteristics in the occurrence and development of synucleinopathies, exists widely, not only in the central nervous system, but also in the peripheral nervous system, submandibular gland, skin, and saliva gland [72], making it a good candidate as a diagnostic biomarker, especially at the early stage of the disease.

About five years ago, studies provided evidence that α-synuclein was present in the CSF from PD patients [73]; however, the role of α-synuclein species in PD prognosis remains unclear [74]. Subsequently, some studies tested the level of α-synuclein in plasma after controlling several major variables; however, unlike CSF, there were no obvious differences between PD patients and controls. Recently, the submandibular gland was shown to be involved in synucleinopathy in the early stages of PD [75]. Consequently, Devic et al. [76] investigated human saliva, and the results seemed positive, suggesting that saliva α-synuclein is another potential biomarker for PDs diagnosis and progression. Recently, the presence of α-synuclein reactive antibodies in the serum of PD patients has become a hot topic [77].

New evidence has emerged indicating that CNS-derived EVs in plasma could serve as diagnostic biomarkers [48]. In addition, other studies have shown that urine harbors EVs; therefore, if the EVs could be isolated successfully, urine would be another example of an easily accessible biofluid [78]. Hypothetically, in addition to testing for α-synuclein itself, the whole structure that generated, transported, and even cleared α-synuclein could be detected. Zange et al. [79] tested skin from 10 patients with multiple system atrophy and 10 with PD together with six control subjects suffering from essential tremor; the phosphorylated α-synuclein in the specimens was examined by immunohistochemistry, and both phosphorylated α-synuclein deposits in skin sympathetic nerve fibers and dermal nerve fiber density were assessed. Their results showed that all patients with PD expressed phosphorylated α-synuclein in sympathetic skin nerve fibers, correlating with age-independent denervation of autonomic skin elements. In contrast, no phosphorylated α-synuclein was found in patients with multiple system atrophy or in the essential tremor-control subjects. These findings supported the view that phosphorylated α-synuclein deposition may cause nerve fiber degeneration in PD. Although the peripheral synuclein tissue is a closer step to diagnosis of PD, Tolosa and Vilas [80] pointed out that Miki et al. [81] and Navarro-Otano et al. [82] made efforts to find abnormal α-synuclein deposition in the gastrointestinal tract and failed. Afterwards, several studies have identified phosphorylated α-synuclein in gastric and colonic specimens, as well as in the salivary glands. However, there are still some important methodological issues that need to be discussed. Firstly, the optimal site of α-synuclein deposits in skin has not yet been identified and current evidence suggests it might occur in skin tissue obtained from the cervical region [83]. Secondly, the number of biopsies needed to obtain a convincing result is also unclear. Thus, further studies are needed to determine the sensitivity and specificity of α-synuclein as a diagnostic biomarker for PD. Eventually, studies targeting testing phosphorylated α-synuclein in the peripheral nervous system in PD are still desperately needed [80]. Studies that aimed to achieve pathological confirmation of PD by biopsying these accessible tissues or chemical examinations evaluating the levels of α-synuclein are summarized in Table 1 [45, 46, 73–77, 83–91]. Currently, the nonmotor symptoms are becoming more and more important in the diagnosis of PD; however, they are always nonspecific and easily ignored by the patients. If physicians could find successfully a way to identify the close relationship between synucleins and the pathology of PD, great progress in the early and differential diagnosis of PD would be made. In addition, there have been few studies targeting synuclein using magnetic resonance or PET; therefore, more research effort is required.

6. Alpha-Synuclein as a Therapeutic Target in PD

There are four common ways to combat the toxicity produced by α-synuclein: decrease α-synuclein aggregation, control its propagation, increase its clearance, and stabilize its existing circumstances. A correct protein balance has a central role in cellular homeostasis of the nervous system [92].

Many mediators participate in the neurotoxicity induced by α-synuclein in synucleinopathies. For example, the
### Table 1: Selected studies targeting \(\alpha\)-synuclein as biomarker for the diagnosis of PD.

| Ref | Materials | Analytical/measuring methods | Results in PD patients compared to controls |
|-----|-----------|------------------------------|------------------------------------------|
| Lebouvier et al., 2008 [84] | Colon tissue | Biopsy and immunohistochemical studies | TH-IR (tyrosine-hydroxylase immunoreactive) neurons were not a marker but phospho-\(\alpha\)-synuclein-IR neurites were found in PD patients |
| Beach et al., 2010 [75] | Lower esophagus and submandibular tissue | Biopsy and a sensitive immunohistochemical method for phosphorylated \(\alpha\)-synuclein | A rostrocaudal gradient of decreasing phosphorylated \(\alpha\)-synuclein histopathology frequency and density |
| Shi et al., 2010 [45] | Alpha-synuclein in plasma | Blood component separation and analysis | No statistical difference was observed |
| Cersósimo et al., 2011 [85] | Salivary gland | Biopsy and immunohistochemical studies | The presence of \(\alpha\)-synuclein inclusions in the submandibular glands |
| Devic et al., 2011 [76] | Saliva | Immunoblotting with a rabbit anti-human \(\alpha\)-synuclein antibody ASY-1 | The level of \(\alpha\)-synuclein decreased |
| Yanamandra et al., 2011 [77] | Alpha-synuclein reactive antibodies in blood sera | ELISA, western blot, and Biacore surface plasmon resonance | Higher antibody levels towards monomeric \(\alpha\)-synuclein |
| Shannon et al., 2012 [86] | Colonic submucosa | Biopsy and immunohistochemical studies | Staining for \(\alpha\)-synuclein in nerve fibers in colonic submucosa |
| Alexoudi et al., 2013 [87] | Submandibular gland | Topic discussion | Relevant PTMs associated with disease progression and severity |
| Schmid et al., 2013 [88] | Alpha-synuclein posttranslational modifications (PTMs) | A new chemical synthesis scheme | Microscopic evidence of the tissue was positive for Lewy type \(\alpha\)-synucleinopathy |
| Adler et al., 2014 [89] | Submandibular gland | Biopsy and immunohistochemical studies | The mean CSF \(\alpha\)-synuclein concentration was significantly lower |
| Gao et al., 2015 [46] | CSF | Meta-analysis | Positive fibers for the \(\alpha\)-synuclein protein were observed |
| Sanchez-Ferro et al., 2015 [90] | Gastric mucosa samples | Biopsy and immunohistochemical studies | Mean concentration of CSF \(\alpha\)-synuclein was slightly decreased; mean concentration of CSF \(\alpha\)-synuclein oligomers was significantly higher |
| Zhou et al., 2015 [73] | CSF | Meta-analysis | The role of \(\alpha\)-synuclein species in PD prognosis remained unsatisfactory |
| Adler et al., 2016 [91] | Submandibular gland | Biopsy and immunohistochemical studies | Positive staining |
| Donadio et al., 2016 [83] | Skin nerve | Skin biopsy | Only 49% of samples with a higher positivity rate for abnormal \(\alpha\)-synuclein deposits at the proximal site in IPD |
| Parnetti et al., 2016 [74] | CSF | Review of 32 selected articles | |
phenomena [94]. Models with human Lewy body-derived α-synuclein assemblies can also be used to prevent cell-to-cell transmission. As discussed above, the spread of α-synuclein includes neuron to neuron, neuron to glia, glia to neuron, and glia to glia [69]. A combination of these methods would allow the identification of potential therapeutics.

The two major degradation systems are autophagy and the UPS. The UPS is thought to be responsible for the degradation of misfolded proteins [95]. A study aimed at this system indicated that downregulation of the UPS might contribute to the pathogenesis of PD [66]. Moreover, considering neurodegenerative diseases, aging is the most significant risk factor for the development of such diseases and is associated with progressive decline of the UPS and accumulation of oxidized proteins [96]. This suggests that targeting these two systems to increase the clearance of α-synuclein might be an efficient treatment for PD in the future.

Many studies have reported the development of powerful tools and models targeting α-synuclein. In addition, much attention is now being paid to the proteotoxic mechanisms and inflammation induced by α-synuclein and how to block them using strategies such as enhancing cellular clearance through innate and adaptive immunization [25]. The accumulation of C-terminal domain truncated α-synuclein can be inhibited by immunotherapy [8]. In addition, improvements in axonal and motor deficits can be achieved by protecting C-terminal domain truncated α-synuclein from C-terminal cleavage [68]. Furthermore, the antibodies that inhibit C-terminal truncation could, theoretically, reduce cell-to-cell propagation of α-synuclein. Immunization with antibodies targeting the C-terminal truncation sites of α-synuclein, the oxidation and nitration of α-synuclein, or even those promoting increased clearance might have therapeutic potential, not only as agents to reduce the amount of α-synuclein itself, but also as inhibitors of its pathological oligomerization and propagation. Several important questions concerning the antibodies remain, the most fundamental one being how antibodies could reach the brain compartment at sufficient levels and how they could recognize their intracellular targeting protein and promote its intracellular toxicity.

Small molecules that stabilize α-synuclein's physiological tetramer could reduce its pathogenicity. The JAK/STAT (Janus kinase/signal transducer and activator of transcription) pathway is known to function in cell proliferation, differentiation, and apoptosis and in immune regulation and hematopoietic cells generation and plays a variety of biological functions in tumorigenesis and neural development. Cytokines such as interleukin, interferon, and epidermal growth factor can contribute to the protection of the nervous system through this pathway, which also provided new insights into the future therapy of PD [97].

7. Conclusion

Alpha-synuclein is a major component of Lewy bodies and Lewy neurites, which are the neuropathological hallmarks of Parkinson's disease. Currently, gene-targeting therapy and biotherapy are hot topics in research into neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, and Huntington's disease. Here, we summarized recent progress targeting this unique protein. However, further research effort is required and several questions remain: What is the specific mechanism of this protein in PD? Do other, as yet undiscovered, gene mutations or duplications or triplications lead to the production of the toxic version of this protein? Did the gene mutations initiate its dysfunction? How can we control the toxic effects of this protein if we aim to limit the accumulation of misfolded proteins without disturbing its physiological function? In conclusion, we still lack critical knowledge necessary to develop α-synuclein as a diagnostic biomarker and therapeutic target.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper and regarding the funding that they have received.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81400933) and the Zhejiang Medical Science and Technology Plan Project (2016KYB119).

References

[1] W. G. Meissner, M. Frasier, T. Gasser et al., “Priorities in Parkinson’s disease research,” Nature Reviews Drug Discovery, vol. 10, no. 5, pp. 377–393, 2011.
[2] W. Peelants, L. Bossuet, A. Van der Perren et al., “α-synuclein strains cause distinct synucleinopathies after local and systemic administration,” Nature, vol. 522, no. 7556, pp. 340–344, 2015.
[3] K. Wakabayashi, K. Tanji, S. Odagiri, Y. Miki, F. Mori, and H. Takahashi, “The Lewy body in Parkinson’s disease and related neurodegenerative disorders,” Molecular Neurobiology, vol. 47, no. 2, pp. 495–508, 2013.
[4] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson’s disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997.
[5] E.-K. Tan, V. R. Chandran, S. Fook-Chong et al., “Alpha-synuclein mRNA expression in sporadic Parkinson’s disease,” Movement Disorders, vol. 20, no. 5, pp. 620–623, 2005.
[6] E. Angot, J. A. Steiner, C. M. Tomé et al., “Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo,” PLoS ONE, vol. 7, no. 6, Article ID e93465, 2012.
[7] A. Recasens and B. Dehay, “Alpha-synuclein spreading in Parkinson’s disease,” Frontiers in Neuroanatomy, vol. 8, article 159, 2014.
[8] H. T. Tran, C.-Y. Chung, M. Iba et al., “α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration,” Cell Reports, vol. 7, no. 6, pp. 2054–2065, 2014.
[9] B. S. Connolly and A. E. Lang, “Pharmacological treatment of Parkinson disease: a review,” The Journal of the American Medical Association, vol. 311, no. 16, pp. 1670–1683, 2014.
[10] B. Dehay, M. Bourdenx, P. Gorry et al., “Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations,” The Lancet Neurology, vol. 14, no. 8, pp. 855–866, 2015.
[11] H. A. Lashuel, C. R. Overk, A. Oueslati, and E. Masliah, “The many faces of α-synuclein: from structure and toxicity to therapeutic target,” *Nature Reviews Neuroscience*, vol. 14, no. 1, pp. 38–48, 2013.

[12] R. Jakes, M. G. Spillantini, and M. Goedert, “Identification of two distinct synucleins from human brain,” *FEBS Letters*, vol. 345, no. 1, pp. 27–32, 1994.

[13] R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease,” *Nature Genetics*, vol. 18, no. 2, pp. 106–108, 1998.

[14] J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” *Annals of Neurology*, vol. 55, no. 2, pp. 164–173, 2004.

[15] S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion et al., “The synucleins,” *Biological Chemistry*, vol. 381, no. 6, pp. 813–818, 2013.

[16] S. Lesage, M. Anheim, F. Letourneur et al., “Gsi1D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome,” *Annals of Neurology*, vol. 73, no. 4, pp. 459–471, 2013.

[17] P. Pasanen, L. Myllykangas, M. Siitonen et al., “A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson’s disease-type pathology,” *Neurobiology of Aging*, vol. 35, no. 9, pp. 2180.e1–2180.e5, 2014.

[18] J. M. George, “The synucleins,” *Genome Biology*, vol. 3, Article ID REVIEW3002, 2002.

[19] B. I. Giasson, I. V. J. Murray, J. Q. Trojanowski, and V. M. Y. Lee, “A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly,” *The Journal of Biological Chemistry*, vol. 276, no. 4, pp. 2380–2386, 2001.

[20] D. Games, E. Valera, B. Spencer et al., “Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models,” *Journal of Neuroscience*, vol. 34, no. 28, pp. 9441–9454, 2014.

[21] D. E. Mor, S. E. Ugras, M. J. Daniels, and H. Ischiropoulos, “Dynamic structural flexibility of α-synuclein,” *Neurobiology of Disease*, vol. 88, pp. 66–74, 2016.

[22] T. Bartels, J. G. Choi, and D. J. Selkoe, “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation,” *Nature*, vol. 477, no. 7362, pp. 107–110, 2011.

[23] J. Burrcé, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton, and T. C. Südhof, “α-Synuclein promotes SNARE-complex assembly in vivo and in vitro,” *Science*, vol. 329, no. 5999, pp. 1663–1667, 2010.

[24] J. Burrcé, S. Vivona, J. Diao, M. Sharma, A. T. Brunger, and T. C. Südhof, “Properties of native brain α-synuclein,” *Nature*, vol. 498, no. 7453, pp. E4–E6, 2013.

[25] H. E. A. Reish and D. G. Standaert, “Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease,” *Journal of Parkinson’s Disease*, vol. 5, no. 1, pp. 1–19, 2015.

[26] D. Lee, S.-Y. Lee, E.-N. Lee, C.-S. Chang, and S. R. Paik, “α-synuclein exhibits competitive interaction between calmodulin and synthetic membranes,” *Journal of Neurochemistry*, vol. 82, no. 5, pp. 1007–1017, 2002.

[27] V. M. Nemani, W. Lu, V. Berge et al., “Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis,” *Neuron*, vol. 65, no. 1, pp. 66–79, 2010.
Parkinson’s Disease

[43] J. L. Webb, B. Ravikumar, J. Atkins, J. N. Skepper, and D. C. Rubinsztein, “α-Synuclein is degraded by both autophagy and the proteasome,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 25009–25013, 2003.

[44] D. Ebrahimi-Fakhari, I. Cantuti-Castelvetri, Z. Fan et al., “Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein,” The Journal of Neuroscience, vol. 31, no. 41, pp. 14508–14520, 2011.

[45] M. Shi, C. P. Zabetian, A. M. Hancock et al., “Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease,” Neuroscience Letters, vol. 480, no. 1, pp. 78–82, 2010.

[46] L. Gao, H. Tang, K. Nie et al., “Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis,” International Journal of Neuroscience, vol. 125, no. 9, pp. 645–654, 2015.

[47] E. Emmanouilidou, K. Melachroinou, T. Roumeliotis et al., “Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival,” Journal of Neuroscience, vol. 30, no. 20, pp. 6838–6851, 2010.

[48] C. Lööv, C. R. Scherzer, B. T. Hyman, X. O. Breakfield, and C.P.Lai, E.Y.Kim, C.E.Badretal., “Visualization and tracking F.Lelan, L.Lescaudron, C.Boyeretal.,” Effectsofhumanalpha-synuclein aggregation by exosomes,” FEBS Letters, vol. 542, no. 1–3, pp. 147–152, 2003.

[49] M. Grey, C. J. Dunning, R. Gaspar et al., “Acceleration of alpha-synuclein aggregation by exosomes,” Journal of Biological Chemistry, vol. 290, no. 5, pp. 2969–2982, 2015.

[50] C. P. Iai, E. Y. Kim, C. E. Badr et al., “Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters,” Nature Communications, vol. 6, article 7029, 2015.

[51] S. B. Prusiner, “A unifying role for prions in neurodegenerative diseases,” Science, vol. 336, no. 6088, pp. 1511–1513, 2012.

[52] P. Desplats, H.-J. Lee, E.-J. Bae et al., “Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 31, pp. 13010–13015, 2009.

[53] C. Hansen, E. Angot, A.-L. Bergström et al., “α-Synuclein propagates from mouse brain to graffed dopaminergic neurons and seeds aggregation in cultured human cells,” The Journal of Clinical Investigation, vol. 121, no. 2, pp. 715–725, 2011.

[54] K. C. Luk, V. Kehm, J. Carroll et al., “Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice,” Science, vol. 338, no. 6109, pp. 949–953, 2012.

[55] K. C. Luk, V. M. Kehm, B. Zhang, P. O’Brien, J. Q. Trojanowski, and V. M. Y. Lee, “Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice,” The Journal of Experimental Medicine, vol. 209, no. 5, pp. 975–986, 2012.

[56] F. Lelan, L. Lescaudron, C. Boyer et al., “Effects of human alpha-synuclein A3T–A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease,” Parkinson’s Disease, vol. 2011, Article ID 987084, 11 pages, 2011.

[57] S. Aulic, T. T. N. Le, F. Moda et al., “Defined α-synuclein prion-like molecular assemblies spreading in cell culture,” BMC Neuroscience, vol. 15, article 69, 2014.

[58] A. Ulusoy, R. E. Musgrove, R. Rusconi et al., “Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury,” Acta Neuropathologica Communications, vol. 3, article 13, 2015.

[59] A. Abeliovich, Y. Schmitz, I. Farinas et al., “Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000.

[60] S. Chandra, F. Fornai, H.-B. Kwon et al., “Double-knockout mice for α- and β-synucleins: effect on synaptic functions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14966–14971, 2004.

[61] V. S. Kokhan, M. A. Afanasyeva, and G. I. Van’kin, “α-Synuclein knockout mice have cognitive impairments,” Behavioural Brain Research, vol. 231, no. 1, pp. 226–230, 2012.

[62] T. Wang and J. C. Hay, “Alpha-synuclein toxicity in the early secretory pathway: how it drives neurodegeneration in Parkinson’s disease,” Frontiers in Neuroscience, vol. 9, article 433, 2015.

[63] E. H. Norris, B. I. Giasson, H. Ischiropoulos, and V. M.-Y. Lee, “Effects of oxidative and nitrative challenges on α-synuclein fibrillogenesis involve distinct mechanisms of protein modifications,” The Journal of Biological Chemistry, vol. 278, no. 29, pp. 27230–27240, 2003.

[64] G. Yamin, V. N. Uversky, and A. L. Fink, “Nitration inhibits fibrillation of human α-synuclein in vitro by formation of soluble oligomers,” FEBS Letters, vol. 542, no. 1–3, pp. 147–152, 2003.

[65] M. Martinez-Vicente, “Autophagy in neurodegenerative diseases: from pathogenic dysfunction to therapeutic modulation,” Seminars in Cell and Developmental Biology, vol. 40, pp. 115–126, 2015.

[66] F. J. A. Dennissen, N. Kholod, and F. W. van Leeuwen, “The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?” Progress in Neurobiology, vol. 96, no. 2, pp. 190–207, 2012.

[67] M. Periquet, T. Fulga, L. Myllykangas, M. G. Schlossmacher, and M. B. Feany, “Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo,” The Journal of Neuroscience, vol. 27, no. 12, pp. 3338–3346, 2007.

[68] A. Ulusoy, F. Febbraro, P. H. Jensen, D. Kirik, and M. Romero-Ramos, “Co-expression of C-terminal truncated α-synuclein enhances full-length α-synuclein-induced pathology,” European Journal of Neuroscience, vol. 32, no. 3, pp. 409–422, 2010.

[69] H.-J. Lee, J.-E. Suk, C. Patrick et al., “Direct transfer of α-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies,” The Journal of Biological Chemistry, vol. 285, no. 12, pp. 9262–9272, 2010.

[70] R. M. Rasia, C. W. Bertocnici, D. Marsh et al., “Structural characterization of copper(II) binding to α-synuclein: insights into the bioinorganic chemistry of Parkinson’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 12, pp. 4294–4299, 2005.

[71] A. Binolfi, R. M. Rasia, C. W. Bertocnici et al., “Interaction of α-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement,” Journal of the American Chemical Society, vol. 128, no. 30, pp. 9893–9901, 2006.

[72] M. G. Cersosimo, “Gastrointestinal biopsies for the diagnosis of alpha-synuclein pathology in Parkinson’s disease,” Gastroenterology Research and Practice, vol. 2015, Article ID 476041, 6 pages, 2015.

[73] B. Zhou, M. Wen, W.-F. Yu, C.-L. Zhang, and L. Jiao, “The diagnostic and differential diagnosis utility of cerebrospinal
fluid α-synuclein levels in Parkinson’s disease: a meta-analysis,” *Parkinson’s Disease*, vol. 2015, Article ID 567386, 11 pages, 2015.

[74] L. Parnetti, C. Cicognola, P. Eusebi, and D. Chiasserini, “Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson’s diagnosis and prognosis,” *Biomarkers in Medicine*, vol. 10, no. 1, pp. 35–49, 2016.

[75] T. G. Beach, C. H. Adler, L. I. Sue et al., “Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders,” *Acta Neuropathologica*, vol. 119, no. 6, pp. 689–702, 2010.

[76] I. Devic, H. Hwang, J. S. Edgar et al., “Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease,” *Brain*, vol. 134, no. 7, article e178, 2011.

[77] K. Yanamandra, M. A. Gruden, V. Casaita, R. Mesksys, L. Forsgren, and L. A. Morozova-Roche, “α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson’s disease patients,” *PLoS ONE*, vol. 6, no. 4, Article ID e18513, 2011.

[78] A. Gámez-Valero, S. I. Lozano-Ramos, I. Bancu, R. Lauzurica-Valdemoros, and F. E. Borrás, “Urinary extracellular vesicles as source of biomarkers in kidney diseases,” *Frontiers in Immunology*, vol. 6, article 6, 2015.

[79] L. Zange, C. Noack, K. Hahn, W. Stenzel, and A. Lipp, “Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson’s disease from multiple system atrophy,” *Brain*, vol. 138, no. 8, pp. 2310–2321, 2015.

[80] E. Tolosa and D. Vilas, “Peripheral synuclein tissue markers: a step closer to Parkinson’s disease diagnosis,” *Brain*, vol. 138, no. 8, pp. 2120–2122, 2015.

[81] Y. Miki, M. Tomiyama, T. Ueno et al., “Clinical availability of skin biopsy in the diagnosis of Parkinson’s disease,” *Neuroscience Letters*, vol. 469, no. 3, pp. 357–359, 2010.

[82] J. Navarro-Otano, J. Casanova-Mollà, M. Morales, J. Vallés-Solé, and E. Tolosa, “Cutaneous autonomic denervation in Parkinson’s disease,” *Journal of Neural Transmission*, vol. 122, no. 8, pp. 1149–1155, 2015.

[83] V. Donadio, A. Incensi, C. Piccinini et al., “Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease,” *Annals of Neurology*, vol. 79, no. 2, pp. 306–316, 2016.

[84] T. Lebouvier, T. Chaumette, P. Damier et al., “Pathological lesions in colonic biopsies during Parkinson’s disease,” *Gut*, vol. 57, no. 12, pp. 1741–1743, 2008.

[85] M. G. Cersósimo, C. Perandones, F. E. Micheli et al., “Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson’s disease patients,” *Movement Disorders*, vol. 26, no. 1, pp. 188–190, 2011.

[86] K. M. Shannon, A. Keshavarzian, E. Mutlu et al., “Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease,” *Movement Disorders*, vol. 27, no. 6, pp. 709–715, 2012.

[87] A. Alexoudi, S. A. Schneider, and G. Deuschl, “Submandibular gland biopsy for the diagnosis of Parkinson’s disease,” *Movement Disorders*, vol. 28, no. 6, p. 734, 2013.

[88] A. W. Schmid, B. Fauvet, M. Moniatte, and H. A. Lashuel, “Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies,” *Molecular & Cellular Proteomics*, vol. 12, no. 12, pp. 3543–3558, 2013.

[89] C. H. Adler, B. N. Dugger, M. L. Hinni et al., “Submandibular gland needle biopsy for the diagnosis of Parkinson disease,” *Neurology*, vol. 82, no. 10, pp. 858–864, 2014.

[90] A. Sanchez-Ferro, A. Rabano, M. J. Catalan et al., “In vivo gastric detection of alpha-synuclein inclusions in Parkinson’s disease,” *Movement Disorders*, vol. 30, no. 4, pp. 517–524, 2015.